SureTrader Advertisement Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Highlights from AGN’s 1Q11 CC:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 591
Posts 90,100
Boards Moderated 28
Alias Born 09/05/02
160x600 placeholder
Fresh VW Probes Opened in Germany, California
More Top Equities Stories Of The Day
Correction to Barron's Friday Blog Item on Pfizer-Allergan
With Merger Looming, Pfizer Weighs Plan To Split In Two
Airbus Gains Regulatory Approval for New A320neo Plane
Prescription Skin Drugs Explode in Costs, Study Shows
EPA Seeks to Revoke Approval of Dow Chemical's Enlist Duo Herbicide -- 4th Update
Apple Buys Motion Capture Startup Faceshift -TechCrunch
Here's Are the Real Reasons Comcast Customers Won't Get to Watch Nets, Yankees Games
Intel Taps Rival For Chip Talent
DewDiligence Member Level  Wednesday, 05/04/11 03:11:09 PM
Re: DewDiligence post# 114167
Post # of 197723 
Highlights from AGN’s 1Q11 CC:

• 2011 non-GAAP EPS guidance raised by $0.02 to a range $3.56-3.62 (+14% YoY).

• Botox: $365M, +9% YoY in local currencies. Dysport, the main competitor, remains stuck at a 17% procedure share in US cosmetic indications and a de minimis share in US medical indications share (#msg-62706265, #msg-49695053). Xeomin’s US market share in also de minimis. Worldwide in all indications, Botox has an 80% market share.

• Juvederm franchise: $88M, +47% YoY in local currencies, due in part to inventory stocking for a promotional program aimed at patients who used Botox and Juvederm.

• Latisse: $25M, +34% YoY, +47% QoQ in local currencies due to some inventory stocking. Although 1Q11 was on track with AGN’s forecast of 2011 sales of $100M, Latisse is clearly not ramping up as quickly as I expected when the product was approved in late 2008 (#msg-34424441).

• Only weak product was LapBand: $52M, -16% YoY in local currencies; however, LapBand retained a 73% global market share in the category. (JNJ has the rest.)

• Sales of all AGN products in Latin America increased 32% YoY in dollars, thanks in part to the stronger Brazilian Real.

15% of AGN’s overall sales are in emerging markets; CEO, David Pyott thinks this will go to 25-30% in the next five years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist